Company profilePharmaceutical#275 of 1,318 in Pakistan✓ No DRAP alerts

RAY PHARMA

Pharmaceutical company · 66 brands · 60 molecules

Ranked #5 of 16 companies in Other Ophthalmologicals, Lubricant

66 registered products 26 pharmaceutical brands 60 distinct molecules 0 DRAP alerts

Company overview

66
registered products
26
pharmaceutical brands
60
distinct molecules
12
therapeutic classes
0
DRAP alerts

RAY PHARMA is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 66 product registrations across 60 distinct molecules. Its portfolio is concentrated in Other Ophthalmologicals, Lubricant and Antibiotics For Topical Use. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by RAY

19 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Anti-Infective, Ophthalmologicals 2

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

16
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202616

Top molecules by brand count

Artemether4 brands
Eye4 brands
Gentamicin3 brands
Ezetimibe3 brands
Trimethoprim2 brands
Glimepiride2 brands
Risperidone2 brands
Dorzolamide2 brands
Fusidic Acid2 brands
Tobramycin2 brands

Therapeutic classes

Other Ophthalmologicals, Lubricant · 2Antibiotics For Topical Use · 2Anti-Infective, Ophthalmologicals · 2Antianemic, Iron & All Combination · 1Corticosteroid Combinations, Topical · 1Antimalarials · 1Drugs For Obstructive Airway Diseases, Systemic · 1Decongestants And Antiallergics · 1Mydriatics And Cycloplegics · 1Antiinflammatory Agents And Antiinfectives In Combination · 1Quinolone Antibacterials · 1Antithrombotic Agents · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official54 products · Rs 118.66 – Rs 2,390.58
Median across source: Rs 464.88

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

HELIX PHARMA (PRIVATE) LIMITED holds 109 molecules not in this portfolio
000 I.UAmylaseArtesunateAscorbic AcidAspirinBicalutamide
Atco Pharma International (Pvt) Ltd holds 223 molecules not in this portfolio
Acetylsalicylic AcidAcyclovirAdapaleneAdapleneAlbuterolAminophylline
Horizon Pharmaceuticals (Pvt) Limited holds 133 molecules not in this portfolio
000 I.UAcyclovirAlbendazoleAmoxicillinAmoxycillin BaseArtemether Ii) Lumefantrine

Get the full profile for RAY

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.